Musings from The Power List: Michael May
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
False
Advertisement
Power List
The Power of Policy
September 17, 2026
What one policy change would accelerate progress in drug development and manufacturing? We asked the 2026 Power List.
8 min read
Musings from The Power List: Dajun Yang
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
Musings from The Power List: Ali Tavassoli
By Ali Tavassoli
September 10, 2026
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
8 min read
Musings from The Power List: Miguel Forte
By Miguel Forte
September 8, 2026
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
4 min read
Musings from The Power List: Peng Lu
September 4, 2026
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
2 min read
What Will Drug Development Look Like in 2036?
September 3, 2026
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
7 min read
Musings from The Power List: Christine Allen
By Christine Allen
August 28, 2026
Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise
2 min read
The Biggest Bottlenecks Holding Back Cell and Gene Therapy
August 24, 2026
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
9 min read
Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
